Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued
Company evaluating potential strategic options to optimize shareholder value
Related news for (GRTX)
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals
- Galera Announces Board Approval of Complete Liquidation and Dissolution
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
- Galera Adopts Limited Duration Stockholder Rights Agreement
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates